Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first…